Related Experiment Videos
Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study
Davide Gatti1, Franco Antoniazzi, Rosangela Prizzi
1Department of Rheumatology, University of Verona, Verona, Italy.
Summary
Quarterly intravenous infusions of neridronate significantly improve bone mineral density (BMD) and reduce fracture risk in children with Osteogenesis Imperfecta (OI). This bisphosphonate therapy offers a promising treatment for this rare genetic bone disorder.
Area of Science:
- Pediatric Endocrinology
- Orthopedics
- Pharmacology
Background:
- Osteogenesis Imperfecta (OI) is a genetic disorder causing fragile bones.
- Effective treatments are limited, with few controlled studies in prepubertal children.
- Bisphosphonates show promise but require further clinical validation.
Purpose of the Study:
- To evaluate the efficacy of intravenous neridronate in prepubertal children with OI.
- To assess the impact on bone mineral density (BMD), bone dimensions, and fracture incidence.
- To provide data from a randomized, controlled trial in this specific population.
Main Methods:
- A 3-year randomized controlled trial involving 64 prepubertal children with OI.
- Participants received quarterly intravenous neridronate (2 mg/kg) or no treatment (controls).
- Outcomes measured included BMD, projected bone areas (DXA), height, and fracture incidence.
Main Results:
- Neridronate significantly increased spine and hip BMD (18-25% vs. 3.5-5.7% in controls) within the first year.
- Height and lumbar spine projected area increased significantly more in the neridronate group.
- The neridronate group showed a reduced risk of clinical fractures (relative risk 0.36, p < 0.05).
Conclusions:
- Quarterly intravenous neridronate is effective in increasing BMD in prepubertal children with OI.
- The treatment also promotes increases in height and bone dimensions.
- Neridronate therapy significantly lowers the risk of clinical fractures in this pediatric population.